Cargando…

Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?

Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiong, Chin Sern, Lin, Tzu Ping, Lim, Vivian Yujing, Toh, Tan Boon, Yang, Valerie Shiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463641/
https://www.ncbi.nlm.nih.gov/pubmed/37612756
http://dx.doi.org/10.1186/s40364-023-00513-5
_version_ 1785098279263928320
author Yiong, Chin Sern
Lin, Tzu Ping
Lim, Vivian Yujing
Toh, Tan Boon
Yang, Valerie Shiwen
author_facet Yiong, Chin Sern
Lin, Tzu Ping
Lim, Vivian Yujing
Toh, Tan Boon
Yang, Valerie Shiwen
author_sort Yiong, Chin Sern
collection PubMed
description Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune checkpoint inhibitors (ICIs) are key agents in cancer immunotherapy, demonstrating improved outcomes in many tumor types. However, most patients with sarcoma do not benefit from treatment, highlighting the need for identification and development of predictive biomarkers for response to ICIs. In this review, we first discuss United States (US) Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biomarkers, as well as the limitations of their use in sarcomas. We then review eight potential predictive biomarkers and rationalize their utility in sarcomas. These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and mucin domain-containing protein 3 (TIM-3), TP53 mutation status, B cells, and tertiary lymphoid structures (TLS). Finally, we discuss the potential for TLS as both a predictive and prognostic biomarker for ICI response in sarcomas to be implemented in the clinic.
format Online
Article
Text
id pubmed-10463641
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104636412023-08-30 Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation? Yiong, Chin Sern Lin, Tzu Ping Lim, Vivian Yujing Toh, Tan Boon Yang, Valerie Shiwen Biomark Res Review Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune checkpoint inhibitors (ICIs) are key agents in cancer immunotherapy, demonstrating improved outcomes in many tumor types. However, most patients with sarcoma do not benefit from treatment, highlighting the need for identification and development of predictive biomarkers for response to ICIs. In this review, we first discuss United States (US) Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biomarkers, as well as the limitations of their use in sarcomas. We then review eight potential predictive biomarkers and rationalize their utility in sarcomas. These include gene expression signatures (GES), circulating neutrophil-to-lymphocyte ratio (NLR), indoleamine 2,3-dioxygenase (IDO), lymphocyte activation gene 3 (LAG-3), T cell immunoglobin and mucin domain-containing protein 3 (TIM-3), TP53 mutation status, B cells, and tertiary lymphoid structures (TLS). Finally, we discuss the potential for TLS as both a predictive and prognostic biomarker for ICI response in sarcomas to be implemented in the clinic. BioMed Central 2023-08-23 /pmc/articles/PMC10463641/ /pubmed/37612756 http://dx.doi.org/10.1186/s40364-023-00513-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yiong, Chin Sern
Lin, Tzu Ping
Lim, Vivian Yujing
Toh, Tan Boon
Yang, Valerie Shiwen
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title_full Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title_fullStr Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title_full_unstemmed Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title_short Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
title_sort biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463641/
https://www.ncbi.nlm.nih.gov/pubmed/37612756
http://dx.doi.org/10.1186/s40364-023-00513-5
work_keys_str_mv AT yiongchinsern biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation
AT lintzuping biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation
AT limvivianyujing biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation
AT tohtanboon biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation
AT yangvalerieshiwen biomarkersforimmunecheckpointinhibitioninsarcomasareweclosetoclinicalimplementation